Takeda Pharmaceutical News

6-K: U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Apr 19 06:15 ET

Takeda Pharmaceutical | 6-K: Notice Regarding Issuance of JPY Hybrid Bonds

Apr 15 06:33 ET

Takeda Pharmaceutical | 6-K: Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Mar 27 06:38 ET

Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

Feb 9 06:09 ET

Takeda Pharmaceutical | 6-K: Takeda Announces Chief Financial Officer Succession

Feb 1 06:21 ET

Takeda Pharmaceutical | 6-K: Announcement of a company split (simplified absorption-type company split/short-form company split) with a wholly-owned subsidiary

Jan 16 00:00 ET

Takeda Pharmaceutical | 6-K: Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA

Nov 13, 2023 06:05 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 26, 2023 06:22 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 18, 2023 06:21 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 18, 2023 06:20 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 2, 2023 06:17 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Sep 28, 2023 06:17 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Sep 11, 2023 06:50 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jul 3, 2023 06:02 ET

Takeda Pharmaceutical | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Jun 28, 2023 06:35 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 28, 2023 06:02 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 23, 2023 06:10 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 9, 2023 06:03 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 1, 2023 06:02 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

May 30, 2023 06:19 ET